Business Context and Reporting Period
This Form 8-K filing by Altimmune, Inc. reports a corporate action approved on September 7, 2018, and effective September 13, 2018. The company is incorporated in Delaware and operates as a biopharmaceutical entity.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. The document focuses exclusively on capital structure adjustments.
Material Changes
- Reverse Stock Split: A one-for-thirty (1:30) reverse stock split was implemented. This reduces outstanding shares from approximately 43 million to approximately 1.4 million.
- Authorized Shares: The number of authorized common shares increased from 100,000,000 to 200,000,000.
- Trading Details: Consolidated common stock began trading on a split-adjusted basis on the Nasdaq Global Market on September 14, 2018.
- Fractional Shares: No fractional shares were issued; all fractional shares were rounded up to the nearest whole share.
- CUSIP Update: The new CUSIP for the common stock is 02155H 200.
Guidance, Outlook, and Risks
The filing contains no financial guidance, management commentary on future performance, or discussion of specific risks beyond the mechanics of the stock split. The action was taken within a range (1-for-5 to 1-for-30) previously approved by stockholders.
Investor Verification Checklist
- Verify the post-split share count of approximately 1.4 million shares.
- Confirm the new CUSIP number (02155H 200) for trading purposes.
- Review the impact of the share reduction on the company's compliance with Nasdaq listing standards.
- Check subsequent filings for any dilution effects from the increase in authorized shares.